2018.Jul.08

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

Date of occurrence of the event: Jul 7, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office Reciprocal shareholding ratios: N/A Cause of occurrence: On Jul 6, 2018 (US Time), OBI Pharma received a notice from the FDA for orphan drug designation for OBI-3424 in treating […]

HOMEWhat’s NewAnnouncementsOBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Hepatocellular Carcinoma (HCC)

Back to List

This article is password protected.

To view the content, please enter your password in the field below

2018.Jun.27

Announcement on the board resolution at Annual General Meeting 2018

2018.Jul.27

Investigational Device Exemption (IDE) for the development of Adagloxad Simolenin (OBI-822) was approved by the US Food and Drug Administration (FDA) for its use in OBI-822 Phase III Clinical Trial